Advertisement
| american gene technologies hiv cure: Denying AIDS Seth C. Kalichman, 2009-01-16 Paralleling the discovery of HIV and the rise of the AIDS pandemic, a flock of naysayers has dedicated itself to replacing genuine knowledge with destructive misinformation—and spreading from the fringe to the mainstream media and the think tank. Now from the editor of the journal AIDS and Behavior comes a bold exposé of the scientific and sociopolitical forces involved in this toxic evasion. Denying AIDS traces the origins of AIDS dissidents disclaimers during the earliest days of the epidemic and delves into the psychology and politics of the current denial movement in its various incarnations. Seth Kalichman focuses not on the “difficult” or doubting patient, but on organized, widespread forms of denial (including the idea that HIV itself is a myth and HIV treatments are poison) and the junk science, faulty logic, conspiracy theories, and larger forces of homophobia and racism that fuel them. The malignant results of AIDS denial can be seen in those individuals who refuse to be tested, ignore their diagnoses, or reject the treatments that could save their lives. Instead of ignoring these currents, asserts Kalichman, science has a duty to counter them. Among the topics covered: Why AIDS denialism endures, and why science must understand it. Pioneer virus HIV researcher Peter Duesberg’s role in AIDS denialism. Flawed immunological, virological, and pharmacological pseudoscience studies that are central to texts of denialism. The social conservative agenda and the politics of AIDS denial, from the courts to the White House. The impact of HIV misinformation on public health in South Africa. Fighting fiction with reality: anti-denialism and the scientific community. For anyone affected by, interested in, or working with researchers in HIV/AIDS, and public health professionals in general, the insight and vision of Denying AIDS will inspire outrage, discussion, and ultimately action. See http://denyingaids.blogspot.com/ for more information. |
| american gene technologies hiv cure: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| american gene technologies hiv cure: Oversight and Review of Clinical Gene Transfer Protocols Institute of Medicine, Board on Health Sciences Policy, Committee on the Independent Review and Assessment of the Activities of the NIH Recombinant DNA Advisory Committee, 2014-03-27 Gene transfer research is a rapidly advancing field that involves the introduction of a genetic sequence into a human subject for research or diagnostic purposes. Clinical gene transfer trials are subject to regulation by the U.S. Food and Drug Administration (FDA) at the federal level and to oversight by institutional review boards (IRBs) and institutional biosafety committees (IBCs) at the local level before human subjects can be enrolled. In addition, at present all researchers and institutions funded by the National Institutes of Health (NIH) are required by NIH guidelines to submit human gene transfer protocols for advisory review by the NIH Recombinant DNA Advisory Committee (RAC). Some protocols are then selected for individual review and public discussion. Oversight and Review of Clinical Gene Transfer Protocols provides an assessment of the state of existing gene transfer science and the current regulatory and policy context under which research is investigated. This report assesses whether the current oversight of individual gene transfer protocols by the RAC continues to be necessary and offers recommendations concerning the criteria the NIH should employ to determine whether individual protocols should receive public review. The focus of this report is on the standards the RAC and NIH should use in exercising its oversight function. Oversight and Review of Clinical Gene Transfer Protocols will assist not only the RAC, but also research institutions and the general public with respect to utilizing and improving existing oversight processes. |
| american gene technologies hiv cure: HIV Vaccines and Cure Linqi Zhang, Sharon R. Lewin, 2018-07-20 This book provides a comprehensive review of the major barriers to HIV cure and vaccine. It covers the fundamental virology and immunology leading to HIV transmission, protection from infection and long term HIV persistence on antiretroviral therapy. In addition, strategies being tested to eliminate persistent HIV and the rational design of vaccines to induce protective immunity are covered. This book also discusses the challenges related to the design of clinical trials for testing the safety and efficacy of these innovative approaches. This book will provide a systematic overview and also discuss controversial issues for researchers in virology and immunology, as well as practicing physicians, and scientists in the pharmaceutical industry. |
| american gene technologies hiv cure: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| american gene technologies hiv cure: The Forever Fix Ricki Lewis, 2012-03-13 Fascinating narrative science that explores the next frontier in medicine and genetics through the very personal prism of the children and families gene therapy has touched. Eight-year-old Corey Haas was nearly blind from a hereditary disorder when his sight was restored through a delicate procedure that made medical history. Like something from a science fiction novel, doctors carefully injected viruses bearing healing genes into the DNA of Corey's eyes—a few days later, Corey could see, his sight restored by gene therapy. THE FOREVER FIX is the first book to tell the fascinating story of gene therapy: how it works, the science behind it, how patients (mostly children) have been helped and harmed, and how scientists learned from each trial to get one step closer to its immense promise, the promise of a forever fix, - a cure that, by fixing problems at their genetic root, does not need further surgery or medication. Told through the voices of the children and families who have been the inspiration, experimental subjects, and successes of genetic science, THE FOREVER FIX is compelling and engaging narrative science that tells explores the future of medicine as well as the families and scientists who are breaking new ground every day. |
| american gene technologies hiv cure: House on Fire William H. Foege, Milbank Memorial Fund, 2011-06-06 “Bill Foege takes us inside the world's greatest public health triumph: the eradication of smallpox. It's a story of true determination, passion and courage. The story of smallpox should encourage all of us to continue the critical work of worldwide disease eradication.”--Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation “Bill Foege is one of the public health giants of our times. He was responsible for the design of the campaign that eradicated smallpox—the most important global health achievement in history and possibly the greatest feat in any field of international cooperation. His insights into the nature of this major event will undoubtedly help to meet the global health challenges of the 21st century.”—Julio Frenk, M.D, PhD, Dean, Harvard School of Public Health “The eradication of a disease has long been the holy grail of global health and Bill Foege found it: more than any other person, he was responsible for the eradication of smallpox from the face of the earth. This is a story told by a remarkably humble man, about the extraordinary coalition that he helped to build, and the most impressive global health accomplishment the world has ever seen.”—Mark Rosenberg, author of Real Collaboration: What It Takes for Global Health to Succeed “I am thrilled that Bill Foege, one of the great heroes of the smallpox eradication campaign, has written this important book. It tells a beautiful human story of an incredible public health triumph, and is full of lessons that could be applied to many of the global challenges we face today.”—Helene D. Gayle MD, President and CEO, CARE USA “Bill Foege’s House on Fire is the first-hand account of how a revised strategy to eradicate smallpox was tested, validated, and applied. Without the global adoption of this new surveillance strategy, the final deathblow to this longtime global menace might never have been dealt.”—Adetokunbo O. Lucas, MD, DSc, author of It Was The Best of Times: From Local to Global Health “Smallpox is the most devastating disease the world has known, as it destroyed lives and shaped history over the centuries. House on Fire provides a day-to-day account by my friend Dr. Bill Foege of the battle required to defeat this wily and diabolic virus.--President Jimmy Carter |
| american gene technologies hiv cure: Public Health Research Methods Greg Guest, Emily E. Namey, 2015 Providing a comprehensive foundation for planning, executing, and monitoring public health research of all types, this book goes beyond traditional epidemiologic research designs to cover technology-based approaches emerging in the new public health landscape. |
| american gene technologies hiv cure: The Social Impact of AIDS in the United States National Research Council, Division of Behavioral and Social Sciences and Education, Commission on Behavioral and Social Sciences and Education, Panel on Monitoring the Social Impact of the AIDS Epidemic, 1993-02-01 Europe's Black Death contributed to the rise of nation states, mercantile economies, and even the Reformation. Will the AIDS epidemic have similar dramatic effects on the social and political landscape of the twenty-first century? This readable volume looks at the impact of AIDS since its emergence and suggests its effects in the next decade, when a million or more Americans will likely die of the disease. The Social Impact of AIDS in the United States addresses some of the most sensitive and controversial issues in the public debate over AIDS. This landmark book explores how AIDS has affected fundamental policies and practices in our major institutions, examining: How America's major religious organizations have dealt with sometimes conflicting values: the imperative of care for the sick versus traditional views of homosexuality and drug use. Hotly debated public health measures, such as HIV antibody testing and screening, tracing of sexual contacts, and quarantine. The potential risk of HIV infection to and from health care workers. How AIDS activists have brought about major change in the way new drugs are brought to the marketplace. The impact of AIDS on community-based organizations, from volunteers caring for individuals to the highly political ACT-UP organization. Coping with HIV infection in prisons. Two case studies shed light on HIV and the family relationship. One reports on some efforts to gain legal recognition for nonmarital relationships, and the other examines foster care programs for newborns with the HIV virus. A case study of New York City details how selected institutions interact to give what may be a picture of AIDS in the future. This clear and comprehensive presentation will be of interest to anyone concerned about AIDS and its impact on the country: health professionals, sociologists, psychologists, advocates for at-risk populations, and interested individuals. |
| american gene technologies hiv cure: Splicing Life United States. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982 |
| american gene technologies hiv cure: Regulatory Aspects of Gene Therapy and Cell Therapy Products Maria Cristina Galli, Mercedes Serabian, 2015-09-15 This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent must-know guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals. |
| american gene technologies hiv cure: Assessing Genetic Risks Institute of Medicine, Committee on Assessing Genetic Risks, 1994-01-01 Raising hopes for disease treatment and prevention, but also the specter of discrimination and designer genes, genetic testing is potentially one of the most socially explosive developments of our time. This book presents a current assessment of this rapidly evolving field, offering principles for actions and research and recommendations on key issues in genetic testing and screening. Advantages of early genetic knowledge are balanced with issues associated with such knowledge: availability of treatment, privacy and discrimination, personal decision-making, public health objectives, cost, and more. Among the important issues covered: Quality control in genetic testing. Appropriate roles for public agencies, private health practitioners, and laboratories. Value-neutral education and counseling for persons considering testing. Use of test results in insurance, employment, and other settings. |
| american gene technologies hiv cure: The Perfect Predator Steffanie Strathdee, Thomas Patterson, 2019-02-26 An electrifying memoir of one woman's extraordinary effort to save her husband's life-and the discovery of a forgotten cure that has the potential to save millions more. A memoir that reads like a thriller. -New York Times Book Review A fascinating and terrifying peek into the devastating outcomes of antibiotic misuse-and what happens when standard health care falls short. -Scientific American Epidemiologist Steffanie Strathdee and her husband, psychologist Tom Patterson, were vacationing in Egypt when Tom came down with a stomach bug. What at first seemed like a case of food poisoning quickly turned critical, and by the time Tom had been transferred via emergency medevac to the world-class medical center at UC San Diego, where both he and Steffanie worked, blood work revealed why modern medicine was failing: Tom was fighting one of the most dangerous, antibiotic-resistant bacteria in the world. Frantic, Steffanie combed through research old and new and came across phage therapy: the idea that the right virus, aka the perfect predator, can kill even the most lethal bacteria. Phage treatment had fallen out of favor almost 100 years ago, after antibiotic use went mainstream. Now, with time running out, Steffanie appealed to phage researchers all over the world for help. She found allies at the FDA, researchers from Texas A&M, and a clandestine Navy biomedical center -- and together they resurrected a forgotten cure. A nail-biting medical mystery, The Perfect Predator is a story of love and survival against all odds, and the (re)discovery of a powerful new weapon in the global superbug crisis. |
| american gene technologies hiv cure: Gene Therapy for HIV and Chronic Infections Ben Berkhout, Hildegund C.J. Ertl, Marc S. Weinberg, 2015-03-10 This book centers on gene therapy and gene transfer approaches to prevent or treat chronic virus infections. The main focus is on the Big Three: human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV). Ample anti-HIV drugs are currently available in the clinic and the development of an effective combination therapy has dramatically improved the lifespan and quality of life of infected individuals. A similar trend can already be recognized for HBV and HCV: the development of multiple (directly acting) antiviral drugs and plans to control or even cure the infection. However, approaches that help prevent infection, or which provide long-lasting treatment (such as a cure) remain important goals. Immunization through gene transfer vehicles encoding immunogenic viral proteins shows promise in preventing infections with complex, highly variable, viruses such as HIV-1 or HCV. Gene therapy applications for virus infections have been discussed since the early 1990’s. Whereas a true cure seems difficult to achieve for HIV-1 due to its intrinsic property to deposit its genome into that of the host, such attempts may be within reach for HCV where spontaneous viral clearance occurs in a small percentage of the infected individuals. The prospect of original gene therapy approaches may provide alternative ways to reach the same endpoint by, for example, silencing of CCR5 expression post-transcriptionally. Many alternative antiviral strategies have been developed based on a variety of novel molecular methods: e.g. ribozymes. Some studies have progressed towards pre-clinical animal models and a few antiviral gene therapies have progressed towards clinical trials. This book provides an overview of this rapidly progressing field, while focusing on the interface of gene therapy and immunology/vaccinology. |
| american gene technologies hiv cure: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| american gene technologies hiv cure: Rare Diseases and Orphan Products Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product Development, 2011-04-03 Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development. |
| american gene technologies hiv cure: Fundamentals of HIV Medicine W. David Hardy, 2017 Completely updated for 2017, Fundamentals of HIV Medicine is a comprehensive clinical care publication for the treatment of HIV/AIDS. Published by the American Academy of HIV Medicine, the book offers physicians, pharmacists, nurse practitioners, and other care providers the most up-to-date overview of the latest HIV treatments and guidelines plus online access to CME. The online access expires August 2018. Embodying the AAHIVM's commitment to promoting uniform excellence in care of seropositive patients, Fundamentals of HIV Medicine 2017 empowers health professionals to deliver standardized, life-sustaining treatment to the patients who need it most. It will serve as an essential clinical reference and provide valuable career enrichment to users across the spectrum of HIV care, treatment, and prevention. |
| american gene technologies hiv cure: Molecular and Cellular Therapeutics David Whitehouse, Ralph Rapley, 2012-02-17 Molecular and Cellular Therapeutics aims to bring together key developments in the areas of molecular diagnostics, therapeutics and drug discovery. The book covers topics including diagnostics, therapeutics, model systems, clinical trials and drug discovery. The developing approaches to molecular and cellular therapies, diagnostics and drug discovery are presented in the context of the pathologies they are devised to treat. |
| american gene technologies hiv cure: Disease Control Priorities in Developing Countries Dean T. Jamison, Joel G. Breman, Anthony R. Measham, George Alleyne, Mariam Claeson, David B. Evans, Prabhat Jha, Anne Mills, Philip Musgrove, 2006-04-02 Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries. |
| american gene technologies hiv cure: AIDS Vaccine Research Flossie Wong-Staal, Robert C. Gallo, 2002-02-22 This reference describes the latest advances in the development and design of an HIV preventive vaccine-detailing the pathogenesis and genetic variability of HIV infection for the construction of molecular and therapeutic strategies to reduce the progression and transmission of AIDS. With contributions by universally recognized authorities in the field, AIDS Vaccine Research discusses major obstacles in the identification of a preventive vaccine the role of innate immunity in management of HIV infection the impact of highly active antiretroviral therapy (HAART) on AIDS research the creation of an effective mucosal DNA vaccine the effect of the AIDS epidemic on developing countries Offering nearly 2000 contemporary references to facilitate further study, AIDS Vaccine Research is a timely manual suitable for immunologists, virologists, pathologists, epidemiologists, pharmacologists, microbiologists, hematologists, hepatologists, AIDS researchers, and upper-level undergraduate and graduate students in these disciplines. |
| american gene technologies hiv cure: Strengthening Forensic Science in the United States National Research Council, Division on Engineering and Physical Sciences, Committee on Applied and Theoretical Statistics, Policy and Global Affairs, Committee on Science, Technology, and Law, Committee on Identifying the Needs of the Forensic Sciences Community, 2009-07-29 Scores of talented and dedicated people serve the forensic science community, performing vitally important work. However, they are often constrained by lack of adequate resources, sound policies, and national support. It is clear that change and advancements, both systematic and scientific, are needed in a number of forensic science disciplines to ensure the reliability of work, establish enforceable standards, and promote best practices with consistent application. Strengthening Forensic Science in the United States: A Path Forward provides a detailed plan for addressing these needs and suggests the creation of a new government entity, the National Institute of Forensic Science, to establish and enforce standards within the forensic science community. The benefits of improving and regulating the forensic science disciplines are clear: assisting law enforcement officials, enhancing homeland security, and reducing the risk of wrongful conviction and exoneration. Strengthening Forensic Science in the United States gives a full account of what is needed to advance the forensic science disciplines, including upgrading of systems and organizational structures, better training, widespread adoption of uniform and enforceable best practices, and mandatory certification and accreditation programs. While this book provides an essential call-to-action for congress and policy makers, it also serves as a vital tool for law enforcement agencies, criminal prosecutors and attorneys, and forensic science educators. |
| american gene technologies hiv cure: The Code Breaker Walter Isaacson, 2021-03-09 A Best Book of 2021 by Bloomberg BusinessWeek, Time, and The Washington Post The bestselling author of Leonardo da Vinci and Steve Jobs returns with a “compelling” (The Washington Post) account of how Nobel Prize winner Jennifer Doudna and her colleagues launched a revolution that will allow us to cure diseases, fend off viruses, and have healthier babies. When Jennifer Doudna was in sixth grade, she came home one day to find that her dad had left a paperback titled The Double Helix on her bed. She put it aside, thinking it was one of those detective tales she loved. When she read it on a rainy Saturday, she discovered she was right, in a way. As she sped through the pages, she became enthralled by the intense drama behind the competition to discover the code of life. Even though her high school counselor told her girls didn’t become scientists, she decided she would. Driven by a passion to understand how nature works and to turn discoveries into inventions, she would help to make what the book’s author, James Watson, told her was the most important biological advance since his codiscovery of the structure of DNA. She and her collaborators turned a curiosity of nature into an invention that will transform the human race: an easy-to-use tool that can edit DNA. Known as CRISPR, it opened a brave new world of medical miracles and moral questions. The development of CRISPR and the race to create vaccines for coronavirus will hasten our transition to the next great innovation revolution. The past half-century has been a digital age, based on the microchip, computer, and internet. Now we are entering a life-science revolution. Children who study digital coding will be joined by those who study genetic code. Should we use our new evolution-hacking powers to make us less susceptible to viruses? What a wonderful boon that would be! And what about preventing depression? Hmmm…Should we allow parents, if they can afford it, to enhance the height or muscles or IQ of their kids? After helping to discover CRISPR, Doudna became a leader in wrestling with these moral issues and, with her collaborator Emmanuelle Charpentier, won the Nobel Prize in 2020. Her story is an “enthralling detective story” (Oprah Daily) that involves the most profound wonders of nature, from the origins of life to the future of our species. |
| american gene technologies hiv cure: A Guide to the Clinical Care of Women with HIV Jean R. Anderson, 2005 NOTE: NO FURTHER DISCOUNT FOR THIS PRODUCT ITEM -OVERSRTOCK SALE-- Significantly reduced price. Edited by Jean R. Anderson. This guide addresses the health care needs unique to women with HIV. It targets clinicians who provide primary care to women as well as those seeking an understanding of how to take care of women with HIV/AIDS. This guide includes tables, figures, color plates, resources, references, and indices. This 2005 edition includes new chapters on international issues and nutrition. Edge indexed. |
| american gene technologies hiv cure: Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade World Intellectual Property Organization, 2013 This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies. |
| american gene technologies hiv cure: Human Genetics and Genomics Bruce R. Korf, Mira B. Irons, 2012-11-19 This fourth edition of the best-selling textbook, Human Genetics and Genomics, clearly explains the key principles needed by medical and health sciences students, from the basis of molecular genetics, to clinical applications used in the treatment of both rare and common conditions. A newly expanded Part 1, Basic Principles of Human Genetics, focuses on introducing the reader to key concepts such as Mendelian principles, DNA replication and gene expression. Part 2, Genetics and Genomics in Medical Practice, uses case scenarios to help you engage with current genetic practice. Now featuring full-color diagrams, Human Genetics and Genomics has been rigorously updated to reflect today’s genetics teaching, and includes updated discussion of genetic risk assessment, “single gene” disorders and therapeutics. Key learning features include: Clinical snapshots to help relate science to practice 'Hot topics' boxes that focus on the latest developments in testing, assessment and treatment 'Ethical issues' boxes to prompt further thought and discussion on the implications of genetic developments 'Sources of information' boxes to assist with the practicalities of clinical research and information provision Self-assessment review questions in each chapter Accompanied by the Wiley E-Text digital edition (included in the price of the book), Human Genetics and Genomics is also fully supported by a suite of online resources at www.korfgenetics.com, including: Factsheets on 100 genetic disorders, ideal for study and exam preparation Interactive Multiple Choice Questions (MCQs) with feedback on all answers Links to online resources for further study Figures from the book available as PowerPoint slides, ideal for teaching purposes The perfect companion to the genetics component of both problem-based learning and integrated medical courses, Human Genetics and Genomics presents the ideal balance between the bio-molecular basis of genetics and clinical cases, and provides an invaluable overview for anyone wishing to engage with this fast-moving discipline. |
| american gene technologies hiv cure: Blood Stem Cell Transplantation James O Armitage, John M Goldman, Josy Reiffers, 1998-01-01 Significant progress has been made in recent years in developing the use of peripheral blood as a source of stem cells for transplantation for patients with haematological and non-haematological malignancies. This book presents an overview of many of the scientific and technical advances that have been made, and discusses the clinical applications and results of transplants with blood-derived stem cells. |
| american gene technologies hiv cure: Good Participatory Practice , 2007 These Good Participatory Practice guidelines aim to provide systematic guidance on the roles and responsibilities of entities funding and conducting biomedical HIV prevention trials towards participants and their communities. Such entities include investigators, research staff, pharmaceutical industry sponsors, foundations, government-supported research networks, non-governmental research sponsors, and all others involved in designing, financing, and executing clinical trials research. |
| american gene technologies hiv cure: A History of Haematology Shaun R. McCann, 2016 A beautifully illustrated account of the remarkable developments within haematology, this insightful volume details the scientists and pioneers central to these advances. |
| american gene technologies hiv cure: Sexually Transmitted Infections National Academies of Sciences, Engineering, and Medicine, National Academies Of Sciences Engineeri, Health and Medicine Division, Board On Population Health And Public He, Board on Population Health and Public Health Practice, Committee on Prevention and Control of Sexually Transmitted Infections in the United States, 2021-12-24 One in five people in the United States had a sexually transmitted infection (STI) on any given day in 2018, totaling nearly 68 million estimated infections. STIs are often asymptomatic (especially in women) and are therefore often undiagnosed and unreported. Untreated STIs can have severe health consequences, including chronic pelvic pain, infertility, miscarriage or newborn death, and increased risk of HIV infection, genital and oral cancers, neurological and rheumatological effects. In light of this, the Centers for Disease Control and Prevention, through the National Association of County and City Health Officials, commissioned the National Academies of Sciences, Engineering, and Medicine to convene a committee to examine the prevention and control of sexually transmitted infections in the United States and provide recommendations for action. In 1997, the Institute of Medicine released a report, The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Although significant scientific advances have been made since that time, many of the problems and barriers described in that report persist today; STIs remain an underfunded and comparatively neglected field of public health practice and research. The committee reviewed the current state of STIs in the United States, and the resulting report, Sexually Transmitted Infections: Advancing a Sexual Health Paradigm, provides advice on future public health programs, policy, and research. |
| american gene technologies hiv cure: Regenesis George M Church, Edward Regis, 2014-04-08 A Harvard biologist and master inventor explores how new biotechnologies will enable us to bring species back from the dead, unlock vast supplies of renewable energy, and extend human life. In Regenesis, George Church and science writer Ed Regis explore the possibilities of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. These technologies-far from the out-of-control nightmare depicted in science fiction-have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span. A breathtaking look at the potential of this world-changing technology, Regenesis is nothing less than a guide to the future of life. |
| american gene technologies hiv cure: A Crack In Creation Jennifer A. Doudna, Samuel H. Sternberg, 2017-06-13 BY THE WINNER OF THE 2020 NOBEL PRIZE IN CHEMISTRY | Finalist for the Los Angeles Times Book Prize “A powerful mix of science and ethics . . . This book is required reading for every concerned citizen—the material it covers should be discussed in schools, colleges, and universities throughout the country.”— New York Review of Books Not since the atomic bomb has a technology so alarmed its inventors that they warned the world about its use. That is, until 2015, when biologist Jennifer Doudna called for a worldwide moratorium on the use of the gene-editing tool CRISPR—a revolutionary new technology that she helped create—to make heritable changes in human embryos. The cheapest, simplest, most effective way of manipulating DNA ever known, CRISPR may well give us the cure to HIV, genetic diseases, and some cancers. Yet even the tiniest changes to DNA could have myriad, unforeseeable consequences, to say nothing of the ethical and societal repercussions of intentionally mutating embryos to create “better” humans. Writing with fellow researcher Sam Sternberg, Doudna—who has since won the Nobel Prize for her CRISPR research—shares the thrilling story of her discovery and describes the enormous responsibility that comes with the power to rewrite the code of life. “The future is in our hands as never before, and this book explains the stakes like no other.” — George Lucas “An invaluable account . . . We owe Doudna several times over.” — Guardian |
| american gene technologies hiv cure: Guidelines for Diagnosing and Managing Disseminated Histoplasmosis Among People Living with HIV Pan American Pan American Health Organization, 2020-06-18 Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people living with HIV, among whom the most frequent clinical presentation is disseminated histoplasmosis. The symptoms of disseminated histoplasmosis are non-specific and may be indistinguishable from those of other infectious diseases, especially disseminated tuberculosis (TB), thus complicating diagnosis and treatment. Histoplasmosis is one of the most frequent opportunistic infections caused by fungal pathogens among people living with HIV in the Americas and may be responsible for 5-15% of AIDS-related deaths every year in this Region. These guidelines aim to provide recommendations for the diagnosis, treatment, and management of disseminated histoplasmosis in persons living with HIV. Although the burden of disease is concentrated in the Americas, the recommendations presented within these guidelines are applicable globally. These guidelines were produced in accordance with the World Health Organization (WHO) handbook for guideline development. The Guideline Development Group elaborated the final recommendations based on a systematic review of scientific literature and critical evaluation of the evidence available using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. These guidelines are intended for health-care providers, HIV program managers, policy-makers, national treatment advisory boards, researchers, and other professionals involved in caring for people who either have or may be at risk of developing disseminated histoplasmosis. |
| american gene technologies hiv cure: Experimental Animal Models of Human Diseases Bartholomew Ibeh, 2018-05-23 The world has recorded losses in terms of human life as well as extensive time spent in experimentation with development of new drugs, elucidation of disease mechanism(s), and therapeutic agent discovery. Ethical and legal issues cojoin in slowing down scientific discoveries in medicine and biology. The past two (2) decades, therefore, have seen tremendous attempts that largely are successful in developing animal models with the characteristics of mimicking, approximating, or expressing transplanted human organs/tissues. These models or rather approaches seem to be fast, cost-effective, and easy to maintain compared to primates. This book is a collection of expert essays on animal models of human diseases of global interest. A visible objective of the book is to provide real-time experimental approach to scientists, clinicians, ethicists, medicolegal/medical jurisprudence workers, immunologists, postgraduate students, and vaccinologists and informative and multidisciplinary approach for the identification of new therapeutic targets and biomarkers using animal models as well as investigating the pathogenesis and therapeutic strategies of human diseases. An increased understanding of the genetic, molecular, and cellular mechanisms responsible for the development of human diseases has laid out the foundation for the development of rational therapies mainly with animal models. |
| american gene technologies hiv cure: Red Book Atlas of Pediatric Infectious Diseases American Academy of Pediatrics, 2007 Based on key content from Red Book: 2006 Report of the Committee on Infectious Diseases, 27th Edition, the new Red Bookr Atlas is a useful quick reference tool for the clinical diagnosis and treatment of more than 75 of the most commonly seen pediatric infectious diseases. Includes more than 500 full-color images adjacent to concise diagnostic and treatment guidelines. Essential information on each condition is presented in the precise sequence needed in the clinical setting: Clinical manifestations, Etiology, Epidemiology, Incubation period, Diagnostic tests, Treatment |
| american gene technologies hiv cure: Unequal Treatment Institute of Medicine, Board on Health Sciences Policy, Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2009-02-06 Racial and ethnic disparities in health care are known to reflect access to care and other issues that arise from differing socioeconomic conditions. There is, however, increasing evidence that even after such differences are accounted for, race and ethnicity remain significant predictors of the quality of health care received. In Unequal Treatment, a panel of experts documents this evidence and explores how persons of color experience the health care environment. The book examines how disparities in treatment may arise in health care systems and looks at aspects of the clinical encounter that may contribute to such disparities. Patients' and providers' attitudes, expectations, and behavior are analyzed. How to intervene? Unequal Treatment offers recommendations for improvements in medical care financing, allocation of care, availability of language translation, community-based care, and other arenas. The committee highlights the potential of cross-cultural education to improve provider-patient communication and offers a detailed look at how to integrate cross-cultural learning within the health professions. The book concludes with recommendations for data collection and research initiatives. Unequal Treatment will be vitally important to health care policymakers, administrators, providers, educators, and students as well as advocates for people of color. |
| american gene technologies hiv cure: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis World Health Organization, 2015-04-20 This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly's resolution on prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolution WHA62.15, adopted in 2009, calls on Member States to develop a comprehensive framework for the management and care of patients with drug-resistant TB. The recommendations contained in these guidelines address the most topical questions concerning the programmatic management of drug-resistant TB: case-finding, multidrug resistance, treatment regimens, monitoring the response to treatment, and selecting models of care. The guidelines primarily target staff and medical practitioners working in TB treatment and control, and partners and organizations providing technical and financial support for care of drug-resistant TB in settings where resources are limited. |
| american gene technologies hiv cure: Disease Control Priorities, Third Edition (Volume 6) King K. Holmes, Stefano Bertozzi, Barry R. Bloom, Prabhat Jha, 2017-11-06 Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings. |
| american gene technologies hiv cure: Gene Technology and Social Acceptance Walter P. von Wartburg, Julian Liew, 1999 Communications specialists from large drug companies take genetic engineering as an example of a new technology to explain the issues that rise in society when a new technology emerges. They survey the economic, legislative, environmental, social, ethical, and philosophical responses. Primarily they are concerned with how to facilitate social acceptance, a process they say all sectors of society must take part in and that must address the fears of all sectors. Annotation copyrighted by Book News, Inc., Portland, OR |
| american gene technologies hiv cure: Global Trends 2040 National Intelligence Council, 2021-03 The ongoing COVID-19 pandemic marks the most significant, singular global disruption since World War II, with health, economic, political, and security implications that will ripple for years to come. -Global Trends 2040 (2021) Global Trends 2040-A More Contested World (2021), released by the US National Intelligence Council, is the latest report in its series of reports starting in 1997 about megatrends and the world's future. This report, strongly influenced by the COVID-19 pandemic, paints a bleak picture of the future and describes a contested, fragmented and turbulent world. It specifically discusses the four main trends that will shape tomorrow's world: - Demographics-by 2040, 1.4 billion people will be added mostly in Africa and South Asia. - Economics-increased government debt and concentrated economic power will escalate problems for the poor and middleclass. - Climate-a hotter world will increase water, food, and health insecurity. - Technology-the emergence of new technologies could both solve and cause problems for human life. Students of trends, policymakers, entrepreneurs, academics, journalists and anyone eager for a glimpse into the next decades, will find this report, with colored graphs, essential reading. |
| american gene technologies hiv cure: Emergent Ecologies Eben Kirksey, 2015-11-27 In an era of global warming, natural disasters, endangered species, and devastating pollution, contemporary writing on the environment largely focuses on doomsday scenarios. Eben Kirksey suggests we reject such apocalyptic thinking and instead find possibilities in the wreckage of ongoing disasters, as symbiotic associations of opportunistic plants, animals, and microbes are flourishing in unexpected places. Emergent Ecologies uses artwork and contemporary philosophy to illustrate hopeful opportunities and reframe key problems in conservation biology such as invasive species, extinction, environmental management, and reforestation. Following the flight of capital and nomadic forms of life—through fragmented landscapes of Panama, Costa Rica, and the United States—Kirksey explores how chance encounters, historical accidents, and parasitic invasions have shaped present and future multispecies communities. New generations of thinkers and tinkerers are learning how to care for emergent ecological assemblages—involving frogs, fungal pathogens, ants, monkeys, people, and plants—by seeding them, nurturing them, protecting them, and ultimately letting go. |
AMERICAN GENE TECHNOLOGIES
American Gene Technologies (AGT) is a clinical-stage cell and gene therapy project focused on the development of novel mechanisms to treat, and potentially cure, human immunodeficiency …
A cure for HIV? TCR agents seek to wipe out viral reservoirs
With an effec-tive regimen of three drugs — two nucleoside reverse transcriptase inhibitors and either an integrase or protease or non-nucleotide reverse transcriptase inhibitor — people...
Multiple Treatment Interruptions and Protecting HIV-Specific …
Oct 24, 2023 · American Gene Technologies International Inc. its inability to eradicate the latent virus necessitate further research towards finding an HIV cure. This will. likely require …
Research Toward a Cure October 15, 2024
Research Toward a Cure October 15, 2024 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are …
Safety and durability of AGT103-T autologous T cell therapy …
Nov 14, 2022 · CD4+ T cell responses is a marker of HIV disease, highly correlated with both viremia and natural virus control, and a strong target for therapeutic intervention.
Preclinical Development and Clinical-Scale Manufacturing of …
We developed a cell and gene therapy to reconstitute HIV-speci c CD4 T cells fi and prevent their destruction by HIV. Antigen-speci c CD4 fi T cells will provide helper functions to support …
IMAGINE A WORLD WITHOUT HIV - Addimmune
1. Functional cure would enable a patient’s immune system to suppress the virus below the level of transmissibility, and possibly detectability, without the use of antiretroviral therapy (ART). 2. …
THE FOUNDATION BEHIND A POTENTIAL HIV CURE
with hematopoietic stem cell transplants and gene therapy, American Gene Technologies has designed a family of lentiviruses to tackle HIV. American Gene’s core technology in viral …
Technologies to test HIV drug Maryland’s American Gene
The gene therapy approach aims to fix damage to the immune system caused by HIV by repairing T helper cells and providing “durable virus control,” says a statement released Tuesday.
Target product profile for cell-based and gene-based …
gene therapy-based products aimed at achieving an HIV cure (ie, durable antiretroviral-free viral control). The need for an effective, safe, scalable, affordable, accessible, and acceptable cure …
American Gene Technologies Signs Research Agreement with …
AGT’s prior studies suggested that the enrichment of HIV-specific CD4 T cells in their AGT103-T autologous cell product can provide increased helper and effector activities capable of reducing …
CO Advances in cell and gene therapy for HIV disease: it is …
therapy may soon realize the goal of treating and possibly curing HIV disease. These advances rely on new technologies for cell engineering and new strategies for product manufacturing that …
Gene Therapy Cure Claims Are Premature, Advocates Say
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial. August 13, 2020 By Liz Highleyman Journalists received not one but three …
Research Toward a Cure January 16, 2024 - Treatment Action …
AutoRESIST: HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma NCT04975698 Catherine Bollard, Children's Research Institute Phase II …
1. What is AGT? - americangene.com
AGT’s irst clinical product is a cure for HIV. AGT103-T is a gene therapy product that has undergone a successful clinical phase 1 trial and follow-on analyical treatment interrupion study …
American Gene Technologies Hiv Cure Trial Will End Copy
American Gene Technologies Hiv Cure Trial Will End Bruce R. Korf,Mira B. Irons Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering,
Research Toward a Cure February 14, 2025
Research Toward a Cure February 14, 2025 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are …
American Gene Technologies
Single treatment cures that can eliminate a life time of chronic care symptom management and treatment. Targeted, locally administered therapies that do not cause systemic toxicities. …
The Software Revolution for the Next 100 Years - American …
of therapies for three different indications. The most advanced is cell and gene therapy to cure Human Immunodeficiency Virus (HIV), designated AGT103-T, which employs an ex vivo cell …
CEO Jeff Galvin Believes We Can - American Gene Technologies
pany’s experimental therapy for HIV. “For HIV, we are using a ‘cell therapy’ to improve the immune system to natu-rally suppress and eliminate HIV in the patient’s body. First, we need a …
Target product profile for cell-based and gene-based …
gene therapy-based products aimed at achieving an HIV cure (ie, durable antiretroviral-free viral control). The need for an effective, safe, scalable, affordable, accessible, and acceptable cure …
HIV Cure: How Far We Have Come? - Springer
discussed under headings; CCR5Δ32/Δ32 stem cells transplantation, shock and kill strategy, block and lock strategy, gene therapy and combined strategies. Keywords HIV · AIDS · HIV …
HIV epidemiology, prevention, treatment, and …
Jul 13, 2023 · 2020—to re-energise the global HIV response and keep it . Figure 1: Estimated numbers of people living with HIV, HIV-related deaths, new HIV infections, and antiretroviral …
AGT Granted Fifth Patent Protecting Its Immunotherapy …
American Gene Technologies (AGT) recently was awarded a fifth immuno-oncology patent (“Methods and Composition for the Activation of ... candidate for an HIV Cure into the clinic in …
Research Priorities for an HIV Cure: IAS Global
HIV cure is drawing on these real-world cases, as well as on HIV controllers, to better ... gene therapies ⑥. Successful cure research will require ... and not be limited to adults; it will include …
HYATT REGENCY CHICAGO CHICAGO, ILLINOIS USA …
Gene drive mosquitoes are one potential new technology in the control of malaria vectors. Target Malaria is one of the research projects developing this technology, and in July 2019, the project …
IL284348A - Hiv pre-immunization and immunotherapy
Hiv pre-immunization and immunotherapy Classications A61K39/21 Retroviridae, e.g. equine inf ectious anemia virus View 37 more classications ... 2021-06-24 Application led b y American …
Program Guide - Military Health System
MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM 5 Welcome to the 2024 MHSRS! FOR YOUR INFORMATION n A 2024 MHSRS badge is required to access all sessions and the …
P ipeline Repor t » 2023 - Treatment Action Group
The HIV cure research field has seen significant developments over the past year. The number of apparent cures achieved in people with HIV who received stem cell transplants for cancers has …
Multiple treatment interruptions and protecting HIV-specific …
May 14, 2024 · 1American Gene Technologies International, Inc., Rockville, MD, United States, 2Division of Infectious ... viremia are vital for achieving a functional cure against HIV. In …
Researchers Study CRISPR Gene Editing to Cure HIV - POZ
Dec 28, 2022 · Editing to Cure HIV EBT-101 is novel gene-editing therapy that uses “molecular scissors” to cut HIV out of cells. December 28, 2022 By Liz Highleyman ... Excision’s …
( 12 ) United States Patent - American Gene Technologies
US011007209B2 ( 12 ) United States Patent Lai et al . ( 10 ) Patent No .: US 11,007,209 B2 ( 45 ) Date of Patent : May 18 , 2021 ( 54 ) SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVE
HIV Cure Research - AVAC
HIV Cure Research An Introductory Factsheet April 2020 ... The kill may also involve interventions to intensify or improve the immune response to HIV. Gene therapy/manipulation ome …
Current application of CRISPR/Cas9 gene-editing technique to ...
gag, pol, env, tat, rev, nef, vif, vpr, vpu (Figure 1a). HIV is the causative agent of AIDS in human patients, and it can be transmitted through contact with infected blood or other body
GLOBAL INVESTMENT IN HIV CURE RESEARCH AND …
In 2013, the IAS HIV Cure resource tracking group joined forces with AVAC to estimate global investments in HIV cure research. To date, this collaboration has yielded eight years of …
HIV 感染症の治癒を目指して - 日本エイズ学会
表 2 hiv 感染症の治癒のための必要な重要項目 ・抗hiv 療法なしでウイルス複製をコントロールすることができる宿主の免疫メカニズムを明らかにする ・抗hiv 療法実施時にhiv が潜伏感 …
www.americangene.com
MAI MULTE A TINTA UNI MI ALMAN NA US010036040B2 ( 12 ) United States Patent Pauza et al . ( 10 ) Patent No . : US 10 , 036 , 040 B2 ( 45 ) Date of Patent : * Jul . 31 , 2018 3 ( 5
www.americangene.com
USO10975374B2 ( 12 ) United States Patent Lahusen et al . ( 10 ) Patent No .: US 10,975,374 B2 ( 45 ) Date of Patent : Apr. 13 , 2021 ( 54 ) COMBINATION VECTORS AND METHODS FOR TR
HIV CURE RESEARCH STATUS: QUICK SUMMARY
EVIDENCE THAT AN HIV CURE IS POSSIBLE STEM CELL TRANSPLANT HIV CURE CASES The first clear evidence that an HIV cure is possible came from the case of a single person, …
Advance research to end the HIV pandemic and - oar.nih.gov
• The number of new HIV diagnoses was highest among people aged 25 to 34 years. • Among gay and bisexual men and other MSM, new HIV diagnoses remain disproportionately higher …
TALEN gene editing takes aim on HIV - mmbio.byu.edu
classes of GEEN technologies (Meganucleases, Zinc Fin-ger Nucleases (ZFNs), TALENs, and CRISPR/Cas-9) tested on different targets to develop new HIV gene thera-pies (Han and Li …
Can gene editing drive out HIV and hepatitis viruses from
Aith gene technologies and CAR-T,e attempting ... For chronic HBV infection, a cure may be much closer than for HIV-1 infection. london-based GSK expects to report data
The Genome Revolution ROFILES IN NNOVATION
Sep 4, 2019 · but inter-related technologies: gene therapy, genetically-engineered cell therapy, and gene editing—they hold the potential to be life-changers for patients, game-changers for …
P ipeline Repor t » 2022 - Treatment Action Group
II T 2 3 due to either cancer recurrence or complications of the procedure. 7 Castillejo’s case was first reported at CROI 2019,8 with a paper published simultaneously in the scientific journal …
Modern diagnostic technologies for HIV - The Lancet
HIV technologies provide highly sensitive and specific results in a short turnaround time, they represent a viable and cost-effective option to expand access to testing and, therefore, reach …
Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure …
gene editing technologies in concert could confer cellular resistance to HIV-1. While the CD4, CCR5, CXCR4 axis for cell-free infection has been the most studied, there are a
PowerPoint Presentation
and Healthcare, and serves as a consultant to TFF Pharmaceuticals and American Gene Technologies. (Updated 9/28/22) Dr Th:yrnpson serves as chair of the independent data …
American Gene Technologies: Headquarters
HIV/AIDS, Phenylketonuria, and liver cancer. With a fast-approaching move-in deadline, NEL Direct worked closely with American Gene Technologies to quickly furnish AGT’s new …
Designer Babies: Evaluating the Ethics of Human Gene Editing
the application and commercialization of gene-editing technologies, for exacerbating inequality and discrimination. Introduction In late November 2018, A biophysicist named He Jiankui1 …
PRESENTS SPECTRUM LECTURE& Open House
About American Gene Technologies® American Gene Technologies® (AGT) is a gene therapy company with a proprietary gene-delivery platform for rapidly developing drugs to cure …
CRISPR/Cas9 therapeutics: progress and prospects - Nature
gene expression in vivo, particularly some genetic diseases caused by mutations in a single gene, and gene-editing technology is expected to control the occurrence of diseases at the genetic
MARCH 2023 HIV Cure Research Information Sheet
EVIDENCE THAT AN HIV CURE IS POSSIBLE STEM CELL TRANSPLANT HIV CURE CASES The first clear evidence that an HIV cure is possible came from the case of a single person, …
( 12 ) United States Patent - americangene.com
US011352646B2 ( 12 ) United States Patent ( 10 ) Patent No .: US 11,352,646 B2 Lahusen et al . ( 45 ) Date of Patent : Jun . 7 , 2022 ( 54 ) VECTOR SYSTEM FOR EXPRESSING REGULATOR
IL279520A - Methods and compositons for the activation of …
2017-01-13 Application led by American Gene Tech Int Inc 2021-01-31 Publication of IL279520A 2022-11-01 Publication of IL279520B 2023-03-01 Publication of IL279520B2 Info: Patent …
HIV cure: latest scientific updates - International AIDS Society
• New strategies for delivery of gene therapy in vivo using Adeno Associated Virus or Lipid Nanoparticles (LNP) are a major advance for implementation and are of high interest • We …
FOR IMMEDIATE RELEASE Contact: Robert Bundy 8 ...
Jun 6, 2016 · About American Gene Technologies International, Inc.! American Gene Technologies (AGT) is developing genetic technologies intended to treat and ultimately cure …
HIV Cure in 2025 and Beyond - treatmentactiongroup.org
HIV Cure in 2025 and Beyond Michael Peluso, MD Assistant Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine ... Gene therapy provides the most likely …
Research Priorities for an HIV Cure: IAS Global
HIV cure is drawing on these real-world cases, as well as on HIV controllers, to better ... gene therapies ⑥. Successful cure research will require ... and not be limited to adults; it will include …
Safety and durability of AGT103-T autologous T cell therapy …
1American Gene Technologies ... immune reconstitution, functional cure FrontiersinMedicine 01 frontiersin.org. Muvarak et al. 10.3389/fmed.2022.1044713 Introduction Chronic HIV disease is ...
WCLC 2024 PROGRAM BOOK
Jul 9, 1999 · TABLE OF CONTENTS CONFERENCE SECRETARIAT International Conference Services Ltd. (ICS) 555 Burrard Street (Bentall Center 2) Vancouver, BC, Canada, V7X 1M8 …
INVESTMENT IN CURE RESEARCH: INVESTMENT IN CURE …
• Models for HIV cure or sustainable remission; • (NHMRC)Paediatric HIV cure; • Gene and cell therapy; • Novel biomarkers and technologies to quantify and analyse HIV reservoirs; • Social …
American Gene Technologies Hiv Copy - archive.ncarb.org
American Gene Technologies Hiv Embark on a breathtaking journey through nature and adventure with Crafted by is mesmerizing ebook, American Gene Technologies Hiv . This …
Knowledge From London and Berlin: Finding Threads to a …
dominant in the early and chronic phases of HIV-1 infection. However, variants able touse CXCR4 (X4 viruses) or both CCR5 and CXCR4 (R5X4 viruses) can be isolated from approximately
Multi-stakeholder consensus on a target product profile for …
stakeholders from across HIV cure and related fields (eg, gene therapy) through email correspondence and 30–60 min interviews led by the target product profile working group …
Generation of HIV-resistant cells with a single-domain …
repeat regions17.Currently, there are three clinically approved drugs targeting the HIV-1 entry step: the first is a gp41-derived peptide fusion inhibitor (Enfuvirtide, T-20)18, the second is a ...
CRISPR/Cas9-Mediated CCR5 Ablation in Human …
gene-edited HSC transplantation for an HIV cure to the clinic. INTRODUCTION Hematopoietic stem cell (HSC) transplantation has been widely and successfully applied to treatments of …
Treatment Action Group
TECHNOLOGIES, CURE RESEARCH, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT By: Mike Frick, Annette Gaudino, Mark Harrington, Tim Horn, Richard ...
Spatial technologies to evaluate the HIV-1 reservoir and its ...
Jul 26, 2024 · Tfh precursor cells can be infected by HIV-1-infected lymph node dendritic cells in the T cell zone or after differentiation within the germinal center upon exposure to extracellular …
GeoVax Labs, Inc. GOVX‐OTC - HubSpot
Oct 18, 2017 · HIV Therapeutic Vaccine Development In March 2017, GeoVax began a collaboration with American Gene Technologies International, Inc. (AGT) with the goal of …
Prevention, treatment and cure of HIV infection - Nature
Natur Revie Mly | Vl 21 | O 2023 | 657–670 662 Revie le map.AkeyattributeofmRNAtechnologyisits‘plugandplay’capac …
